{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T18:17:59Z","timestamp":1770401879061,"version":"3.49.0"},"reference-count":47,"publisher":"Spandidos Publications","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2025.15430","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T13:20:42Z","timestamp":1765804842000},"page":"1-11","source":"Crossref","is-referenced-by-count":0,"title":["Identifying myosin heavy chain 11 as a predictive biomarker of prostate cancer progression and antiandrogen resistance"],"prefix":"10.3892","volume":"31","author":[{"given":"Cong","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Urology, Tinglin Hospital of Jinshan District, Shanghai 201505, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Urology, Tinglin Hospital of Jinshan District, Shanghai 201505, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianliang","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Urology, Tinglin Hospital of Jinshan District, Shanghai 201505, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guilin","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Urology, Tinglin Hospital of Jinshan District, Shanghai 201505, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liangming","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Urology, Tinglin Hospital of Jinshan District, Shanghai 201505, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2025,12,15]]},"reference":[{"key":"key20260206094907_b1-ol-31-2-15430","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"key20260206094907_b2-ol-31-2-15430","first-page":"718","article-title":"Statistical analysis of incidence and mortality of prostate cancer in China, 2015","volume":"42","author":"Fu","year":"2020","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"key20260206094907_b3-ol-31-2-15430","doi-asserted-by":"publisher","first-page":"5730","DOI":"10.3390\/molecules27175730","article-title":"Prostate cancer review: Genetics, diagnosis, treatment options, and alternative approaches","volume":"27","author":"Sekhoacha","year":"2022","journal-title":"Molecules"},{"key":"key20260206094907_b4-ol-31-2-15430","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1056\/NEJMp048178","article-title":"Mechanisms of androgen-refractory prostate cancer","volume":"351","author":"Debes","year":"2004","journal-title":"N Engl J Med"},{"key":"key20260206094907_b5-ol-31-2-15430","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/nrc4016","article-title":"Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer","volume":"15","author":"Watson","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"key20260206094907_b6-ol-31-2-15430","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1002\/cncr.23304","article-title":"Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: Association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect","volume":"112","author":"Ross","year":"2008","journal-title":"Cancer"},{"key":"key20260206094907_b7-ol-31-2-15430","doi-asserted-by":"publisher","first-page":"e157","DOI":"10.1016\/j.clgc.2019.09.020","article-title":"Utilization and outcomes of surgical castration in comparison to medical castration in metastatic prostate cancer","volume":"18","author":"Garje","year":"2020","journal-title":"Clin Genitourin Cancer"},{"key":"key20260206094907_b8-ol-31-2-15430","doi-asserted-by":"publisher","first-page":"101032","DOI":"10.1016\/j.neo.2024.101032","article-title":"Epitranscriptomic mechanisms of androgen signalling and prostate cancer","volume":"56","author":"Patke","year":"2024","journal-title":"Neoplasia"},{"key":"key20260206094907_b9-ol-31-2-15430","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1002\/(SICI)1097-0045(19990401)39:1<47::AID-PROS8>3.0.CO;2-X","article-title":"Bicalutamide dosages used in the treatment of prostate cancer","volume":"39","author":"Kolvenbag","year":"1999","journal-title":"Prostate"},{"key":"key20260206094907_b10-ol-31-2-15430","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1007\/s40265-018-1029-9","article-title":"Enzalutamide: A review in Castration-resistant prostate cancer","volume":"78","author":"Scott","year":"2018","journal-title":"Drugs"},{"key":"key20260206094907_b11-ol-31-2-15430","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1158\/0008-5472.CAN-11-3948","article-title":"ARN-509: A novel antiandrogen for prostate cancer treatment","volume":"72","author":"Clegg","year":"2012","journal-title":"Cancer Res"},{"key":"key20260206094907_b12-ol-31-2-15430","first-page":"1582","article-title":"Identification and validation of MSMB as a critical gene for prostate cancer development in obese people","volume":"13","author":"Chen","year":"2023","journal-title":"Am J Cancer Res"},{"key":"key20260206094907_b13-ol-31-2-15430","doi-asserted-by":"publisher","first-page":"1106175","DOI":"10.3389\/fendo.2022.1106175","article-title":"CCNB1 and AURKA are critical genes for prostate cancer progression and castration-resistant prostate cancer resistant to vinblastine","volume":"13","author":"Chen","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"key20260206094907_b14-ol-31-2-15430","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1007\/s12672-024-00973-7","article-title":"Exploration of the influence of GOLGA8B on prostate cancer progression and the resistance of castration-resistant prostate cancer to cabazitaxel","volume":"15","author":"Li","year":"2024","journal-title":"Discov Oncol"},{"key":"key20260206094907_b15-ol-31-2-15430","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1007\/s12672-024-01373-7","article-title":"Identification of BBC3 as a novel indicator for predicting prostate cancer development and olaparib resistance","volume":"15","author":"Ma","year":"2024","journal-title":"Discov Oncol"},{"key":"key20260206094907_b16-ol-31-2-15430","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s40001-022-00730-y","article-title":"CDK6 is upregulated and may be a potential therapeutic target in Enzalutamide-resistant castration-resistant prostate cancer","volume":"27","author":"Chen","year":"2022","journal-title":"Eur J Med Res"},{"key":"key20260206094907_b17-ol-31-2-15430","doi-asserted-by":"publisher","first-page":"D991","DOI":"10.1093\/nar\/gks1193","article-title":"NCBI GEO: Archive for functional genomics data sets-update","volume":"41","author":"Barrett","year":"2013","journal-title":"Nucleic Acids Res"},{"key":"key20260206094907_b18-ol-31-2-15430","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.cell.2018.03.059","article-title":"SnapShot: TCGA-Analyzed tumors","volume":"173","author":"Blum","year":"2018","journal-title":"Cell"},{"key":"key20260206094907_b19-ol-31-2-15430","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41586-020-2135-x","article-title":"A genomic and epigenomic atlas of prostate cancer in Asian populations","volume":"580","author":"Li","year":"2020","journal-title":"Nature"},{"key":"key20260206094907_b20-ol-31-2-15430","doi-asserted-by":"publisher","first-page":"5680","DOI":"10.1038\/s41467-022-33291-z","article-title":"Gene expression based inference of cancer drug sensitivity","volume":"13","author":"Chawla","year":"2022","journal-title":"Nat Commun"},{"key":"key20260206094907_b21-ol-31-2-15430","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1038\/s41467-021-21860-7","article-title":"A noncanonical AR addiction drives enzalutamide resistance in prostate cancer","volume":"12","author":"He","year":"2021","journal-title":"Nat Commun"},{"key":"key20260206094907_b22-ol-31-2-15430","doi-asserted-by":"publisher","first-page":"43713","DOI":"10.18632\/oncotarget.9666","article-title":"Targeting ACLY sensitizes castration-resistant prostate cancer cells to AR antagonism by impinging on an ACLY-AMPK-AR feedback mechanism","volume":"7","author":"Shah","year":"2016","journal-title":"Oncotarget"},{"key":"key20260206094907_b23-ol-31-2-15430","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","article-title":"Limma powers differential expression analyses for RNA-sequencing and microarray studies","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"key20260206094907_b24-ol-31-2-15430","doi-asserted-by":"publisher","first-page":"W98","DOI":"10.1093\/nar\/gkx247","article-title":"GEPIA: A web server for cancer and normal gene expression profiling and interactive analyses","volume":"45","author":"Tang","year":"2017","journal-title":"Nucleic Acids Res"},{"key":"key20260206094907_b25-ol-31-2-15430","doi-asserted-by":"publisher","first-page":"D362","DOI":"10.1093\/nar\/gkw937","article-title":"The STRING database in 2017: Quality-controlled Protein-protein association networks, made broadly accessible","volume":"45","author":"Szklarczyk","year":"2017","journal-title":"Nucleic Acids Res"},{"key":"key20260206094907_b26-ol-31-2-15430","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1101\/gr.1239303","article-title":"Cytoscape: A software environment for integrated models of biomolecular interaction networks","volume":"13","author":"Shannon","year":"2003","journal-title":"Genome Res"},{"key":"key20260206094907_b27-ol-31-2-15430","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1007\/s12672-022-00508-y","article-title":"Identification of hub genes predicting the development of prostate cancer from benign prostate hyperplasia and analyzing their clinical value in prostate cancer by bioinformatic analysis","volume":"13","author":"Chen","year":"2022","journal-title":"Discov Oncol"},{"key":"key20260206094907_b28-ol-31-2-15430","first-page":"4003","article-title":"CYP19A1 is downregulated by BRD4 and suppresses castration-resistant prostate cancer cell invasion and proliferation by decreasing AR expression","volume":"13","author":"Chen","year":"2023","journal-title":"Am J Cancer Res"},{"key":"key20260206094907_b29-ol-31-2-15430","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.eururo.2017.12.018","article-title":"Updates in the eighth edition of the Tumor-Node-Metastasis staging classification for urologic cancers","volume":"73","author":"Paner","year":"2018","journal-title":"Eur Urol"},{"key":"key20260206094907_b30-ol-31-2-15430","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"key20260206094907_b31-ol-31-2-15430","first-page":"175","article-title":"Quantifying the role of PSA screening in the US prostate cancer mortality decline","volume":"19","author":"Etzioni","year":"2008","journal-title":"Cancer Causes Control"},{"key":"key20260206094907_b32-ol-31-2-15430","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/j.urolonc.2010.02.001","article-title":"Current second-line treatment options for patients with castration resistant prostate cancer (CRPC) resistant to docetaxel","volume":"30","author":"Arsov","year":"2012","journal-title":"Urol Oncol"},{"key":"key20260206094907_b33-ol-31-2-15430","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1586\/14737140.4.1.37","article-title":"Bicalutamide (Casodex) in the treatment of prostate cancer","volume":"4","author":"Fradet","year":"2004","journal-title":"Expert Rev Anticancer Ther"},{"key":"key20260206094907_b34-ol-31-2-15430","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1200\/JCO.22.00193","article-title":"Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer","volume":"40","author":"Armstrong","year":"2022","journal-title":"J Clin Oncol"},{"key":"key20260206094907_b35-ol-31-2-15430","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa1715546","article-title":"Apalutamide treatment and Metastasis-free survival in prostate cancer","volume":"378","author":"Smith","year":"2018","journal-title":"N Engl J Med"},{"key":"key20260206094907_b36-ol-31-2-15430","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.ccell.2020.03.001","article-title":"Loss of CHD1 Promotes heterogeneous mechanisms of resistance to AR-Targeted therapy via chromatin dysregulation","volume":"37","author":"Zhang","year":"2020","journal-title":"Cancer Cell"},{"key":"key20260206094907_b37-ol-31-2-15430","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.ccell.2020.06.005","article-title":"Tumor Microenvironment-derived NRG1 promotes antiandrogen resistance in prostate cancer","volume":"38","author":"Zhang","year":"2020","journal-title":"Cancer Cell"},{"key":"key20260206094907_b38-ol-31-2-15430","doi-asserted-by":"publisher","first-page":"e90002","DOI":"10.1371\/journal.pone.0090002","article-title":"Comparative genomic and transcriptomic analyses of LNCaP and C4-2B prostate cancer cell lines","volume":"9","author":"Spans","year":"2014","journal-title":"PLoS One"},{"key":"key20260206094907_b39-ol-31-2-15430","first-page":"3899","article-title":"Clinical and prognostic significance of MYH11 in lung cancer","volume":"19","author":"Nie","year":"2020","journal-title":"Oncol Lett"},{"key":"key20260206094907_b40-ol-31-2-15430","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1089\/omi.2018.0048","article-title":"Drug targeting and biomarkers in head and neck cancers: Insights from systems biology analyses","volume":"22","author":"Islam","year":"2018","journal-title":"OMICS"},{"key":"key20260206094907_b41-ol-31-2-15430","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1186\/s12885-021-08653-3","article-title":"Interaction between DNMT3B and MYH11 via hypermethylation regulates gastric cancer progression","volume":"21","author":"Wang","year":"2021","journal-title":"BMC Cancer"},{"key":"key20260206094907_b42-ol-31-2-15430","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.1038\/s41409-021-01384-w","article-title":"Prognostic values of D816V KIT mutation and Peri-transplant CBFB-MYH11 MRD monitoring on acute myeloid leukemia with CBFB-MYH11","volume":"56","author":"Cho","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"key20260206094907_b43-ol-31-2-15430","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1182\/bloodadvances.2019000709","article-title":"Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CBFB-MYH11","volume":"4","author":"Ishikawa","year":"2020","journal-title":"Blood Adv"},{"key":"key20260206094907_b44-ol-31-2-15430","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1186\/1471-2407-8-263","article-title":"Somatic mutation analysis of MYH11 in breast and prostate cancer","volume":"8","author":"Alhopuro","year":"2008","journal-title":"BMC Cancer"},{"key":"key20260206094907_b45-ol-31-2-15430","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1615\/CritRevEukaryotGeneExpr.2020029243","article-title":"The identification of key gene expression signature in prostate cancer","volume":"30","author":"Huang","year":"2020","journal-title":"Crit Rev Eukaryot Gene Expr"},{"key":"key20260206094907_b46-ol-31-2-15430","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.3390\/cells9122653","article-title":"Androgen receptor signaling pathway in prostate cancer: From genetics to clinical applications","volume":"9","author":"Aurilio","year":"2020","journal-title":"Cells"},{"key":"key20260206094907_b47-ol-31-2-15430","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1095\/biolreprod.112.103556","article-title":"Estrogen-induced maldevelopment of the penis involves down-regulation of myosin heavy chain 11 (MYH11) expression, a biomarker for smooth muscle cell differentiation","volume":"87","author":"Okumu","year":"2012","journal-title":"Biol Reprod"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T07:49:15Z","timestamp":1770364155000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2025.15430"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,15]]},"references-count":47,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,12,15]]}},"URL":"https:\/\/doi.org\/10.3892\/ol.2025.15430","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,15]]}}}